Axonics recognized as a Fierce 15 company in 2017

By Raymond Cohen on

FierceMedTech’s 2017 Fierce 15

by Amirah Al Idrus |
Dec 11, 2017 12:00pm

When we were compiling this year’s crop of Fierce 15 companies, some clear themes stood out. Genomics. Bioelectronics. Artificial intelligence. But while multiple companies are working to improve the use of these technologies, there runs a deeper current: making care more accessible.

For example, Allurion Technologies is developing a weight-loss balloon that is swallowed in an outpatient procedure and is naturally passed from the body at the end of the treatment period.

Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology

By Raymond Cohen on

Irvine, CA, Dec 4, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of bladder and bowel dysfunction, announced today that the United States Patent and Trademark Office has granted Axonics seven new U.S. patents along with numerous foreign counterparts relating to its implantable sacral neuromodulation technology.

The most recently issued patents granted during the second half of 2017 range in subject matter and include coverage of the Company’s external pulse generator,

Axonics® Receives IDE Clearance from U.S. FDA to Conduct a Pivotal Study with its Sacral Neuromodulation System for the Treatment of Urinary Dysfunction

By Raymond Cohen on

Irvine, CA – November 7, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable sacral neuromodulation (r-SNM™) system for the treatment of overactive bladder (OAB) and bowel dysfunction, today announced the U.S. Food & Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) in accordance with 21 CFR 812 regulations allowing Axonics to conduct a pivotal study designed to gain FDA approval in the United States.

Positive Results for the Axonics® RELAX-OAB Clinical Study Presented at the International Continence Society Congress

By Raymond Cohen on

Irvine, CA and Florence, Italy, – September 13, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, today announced the presentation of positive results from its prospective, multicenter clinical study at the 2017 International Continence Society (ICS) Congress in Florence, Italy.

The presentation, entitled “A prospective multicenter clinical study evaluating a miniaturized rechargeable sacral neuromodulation system for the safe and effective treatment of overactive bladder (RELAX-OAB study),” was delivered by Bertil F.M.

Axonics® Appoints Dr. Karen L. Noblett as Chief Medical Officer

By Raymond Cohen on

Irvine, CA – September 6, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, today announced the appointment of Karen L. Noblett, M.D., M.A.S., a urogynecologist and prolific clinical researcher, as Chief Medical Officer.

Dr. Noblett is world renowned for her work in female pelvic medicine with an emphasis on sacral neuromodulation for the treatment of patients with refractory overactive bladder,

Hindsight 20/20: Raymond Cohen by Tina Tan

By Raymond Cohen on

Executive Summary

Hindsight 20/20 is a new Q&A feature where medtech industry veterans share their long experience taking diverse businesses – be they start-ups or publicly-listed entities – from strength to strength and navigating through times of crises. This first instalment shines the spotlight on Raymond Cohen, who is currently CEO of venture-backed sacral neuromodulation company Axonics Modulation Technologies, Inc. The advice he gives includes not rushing into clinical studies too soon, try to go big with the fundraising and be very cautious when tackling a complex market like the US,

Axonics Announces $20.5 Million Second Closing of its Series C Financing

By Raymond Cohen on

Irvine, CA – July 6, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced today that it has completed a $20.5 million second closing of its Series C financing, bringing the total amount of capital raised for its Series C to $35 million.

The second closing of the Series C round included two new investors,

Positive Initial Results of the Axonics® RELAX-OAB Clinical Study Presented at the International Neuromodulation Society World Congress

By Raymond Cohen on

Irvine, CA, and Edinburgh, Scotland, May 31, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, today announced the presentation of positive initial results from its prospective, multicenter clinical study at the 2017 International Neuromodulation Society (INS) World Congress in Edinburgh, Scotland.

The presentation, entitled “A rechargeable sacral neuromodulation system for the treatment of overactive bladder: interim results of a prospective,

Axonics Announces $14.5 Million First Close of Series C Financing

By Raymond Cohen on

Irvine, CA – May 2, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that it has completed a $14.5 million first closing of its Series C financing.

Axonics intends to raise $30 million in its Series C financing. Proceeds from the financing will be used to conduct a pivotal clinical study in Overactive Bladder patients to gain U.S.

Axonics to Present Results of the RELAX-OAB Clinical Study at the International Neuromodulation Society World Congress

By Raymond Cohen on

Irvine, CA, April 18, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that initial results from its prospective, multicenter clinical study will be presented for the first time at the International Neuromodulation Society (INS) World Congress on May 30, 2017 in Edinburgh, Scotland.

Professor Philip Van Kerrebroeck, MD, PhD, Chair of the Dept.